Phase I Studies

CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Bel more

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally optimized more

Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, ran more

We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia. We searched PubMed and regulatory databases to identify targeted drugs approved globally and compared their FAD more

Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated in patients with recurrent or refractory acute myeloid leukaemia (AML) or advanced solid tum more

Summary Aims To characterise the pharmacokinetics (PK) of selumetinib (AZD6244; ARRY‐142886), a MEK1/2 inhibitor in clinical development for numerous indications, and its N‐desmethyl metabolite in healthy volunteers, and evaluate clinically important covariates. Methods A pooledpopulati more